Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer
Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer
Immutep的Efti與MSD的KEYTRUDA在一線頭頸癌中表現出良好的安全性和療效
- Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024
- In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR (34.5% ORR including partial response after data cut-off) versus 18.5% ORR for KEYTRUDA
- Efti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any PD-L1 expression and combination continues to have favourable safety profile
- Statistically significant increase in absolute lymphocyte count biomarker seen in the efti in combination with KEYTRUDA arm shows efti's biological activity in a randomised setting
- Based on the high unmet need and encouraging results to date, with Overall Survival expected in 2025, the path forward will be discussed with regulatory agencies
- 在2024年的ESMO大會上，在備受關注的提供論文口頭報告中發佈了結果。
- 在具有任何PD-L1表達（CPS≥1）的患者中，efti與KEYTRUDA的組合表現最佳，CPS≥20的ORR爲31.0%（包括截止數據後的部分反應，ORR達到34.5%），而KEYTRUDA的ORR爲18.5%。
- 在任何PD-L1表達患者中，efti與KEYTRUDA的聯合治療導致了高達17.5個月的持續反應，並且聯合治療的安全性持續良好。
- 在隨機設定中，efti與KEYTRUDA聯合治療臂中觀察到絕對淋巴細胞計數生物標誌物的統計學顯著增加，顯示了efti的生物活性。
- 基於高度未滿足的需求和迄今爲止令人鼓舞的結果，預計將於2025年觀察到總生存期，未來的發展方向將與監管機構進一步討論。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。